TrialSignal
Clinical trial intelligence report
A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 24, 2026
Report code
NCT03382899-Jun 24, 2026
NCT ID
NCT03382899
Status
TERMINATED
Phase
Phase 2
Sponsor
Eli Lilly and Company
Executive brief
Investment-Ready Snapshot
The CYPRESS-1 trial evaluated the combination of pegilodecakin (AM0010) with pembrolizumab in patients with advanced wild type non-small cell lung cancer (NSCLC) exhibiting high PD-L1 expression. Despite the potential for enhanced efficacy through combination therapy, the trial was terminated early due to an unfavorable risk-benefit ratio. This raises concerns regarding the commercial viability of pegilodecakin in this indication, particularly in a competitive landscape dominated by established therapies such as pembrolizumab alone. The early termination may impact Eli Lilly's strategic positioning and investment in immuno-oncology, necessitating a reassessment of their pipeline and potential partnerships.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03382899
Indication
Non Small Cell Lung Cancer
Modality
protein therapy
Target
PD-1/PD-L1 pathway modulation
Intervention
Pegilodecakin, Pembrolizumab
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.